Table 1. Clinical and pathological characteristics at baseline of the second-line of chemotherapy.

	Overall Population	Second-line therapy without trastuzumab	Second-line therapy with trastuzumab	P-value
	N= 104	N = 65	N = 39
Age				0.41
Mean	60.0	61.3	57.9
Median [range]	60.8 [17.3–80.3]	59.0 [34.0-80.3]	61.1 [17.3-80.1]
Gender				0.53
Male	82 (78.8%)	50 (76.9%)	32 (82.1%)
Female	22 (21.2%)	15 (23.1%)	7 (17.9%)
ECOG PS				0.81
0-1	74 (71.2%)	45 (69.2%)	29 (74.4%)
≥ 2	23 (22.1%)	15 (23.1%)	8 (20.5%)
Unknown	7 (6.7%)	5 (7.7%)	2 (5.1%)
Primary tumor site				<0.0001
Gastro-esophageal junction	57 (54.8%)	25 (38.5%)	32 (82.1%)
Stomach	47 (45.2%)	40 (61.5%)	7 (17.9%)
Histological type				0.06
Intestinal	54 (51.9%)	34 (52.3%)	20 (51.3%)
Diffuse or mixed	12 (11.6%)	4 (6.2%)	8 (20.5%)
Other or unknown	38 (36.5%)	27 (41.5%)	11 (28.2%)
Tumor grade				0.41
Well/Moderately differentiated	63 (60.6%)	37 (56.9%)	26 (66.7%)
Poorly differentiated	29 (27.9%)	21 (32.3%)	8 (20.5%)
Unknown or missing	12 (11.5%)	7 (10.8%)	5 (12.8%)
Extent of disease				0.15
Locally advanced	1 (1.0%)	0 (0%)	1 (2.5%)
Metastatic	103 (99.0%)	65 (100%)	38 (97.5%)
Measurable disease	91 (87.5%)	55 (84.6%)	36 (92.3%)	0.32
Number of metastatic sites				0.03
0-1	32 (30.8%)	15 (23.1%)	17 (43.6%)
≥2	72 (69.2%)	50 (76.9%)	22 (56.4%)
HER2 status				0.16
IHC 3+	83 (79.8%)	49 (75.4%)	34 (87.2%)
IHC 2+/FISH-positive	17 (16.4%)	14 (21.5%)	3 (7.7%)
Unknown	4 (3.8%)	2 (3.1%)	2 (5.1%)
First-line chemotherapy regimen				<0.0001
FP + oxaliplatin + trastuzumab	50 (48.1%)	21 (32.3%)	29 (74.4%)
FP + cisplatin + trastuzumab	54 (51.9%)	44 (67.7%)	10 (25.6%)
Second-line chemotherapy regimen				0.03
FOLFIRI	67 (64.4%)	48 (73.9%)	19 (48.7%)
Taxane	23 (22.1%)	11 (16.9%)	12 (30.8%)
FP + platinum salts	14 (13.5%)	6 (9.2%)	8 (20.5%)

Abbreviations: IHC, immunohistochemistry; FISH, fluorescence in-situ hybridization; FP, Fluoropyrimidine